Relief Therapeutics Holding SA's latest marketcap:
As of 07/28/2025, Relief Therapeutics Holding SA's market capitalization has reached $36.59 M. According to our data, Relief Therapeutics Holding SA is the 32367th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 36.59 M |
| Revenue (ttm) | 10.58 M |
| Net Income (ttm) | -21,514,389.84 |
| Shares Out | 12.57 M |
| EPS (ttm) | -1.72 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/27/2025 |
Relief Therapeutics Holding SA's yearly market capitalization.
| Date | Market Cap(₣) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/28/2025 | ₣29.11 M | $36.59 M | -44.86% | 32367 |
| 12/30/2024 | ₣52.8 M | $58.13 M | 111.56% | 26951 |
| 12/29/2023 | ₣24.96 M | $29.64 M | -81.09% | 31241 |
| 12/30/2022 | ₣131.96 M | $142.66 M | -51.9% | 20066 |
| 12/30/2021 | ₣274.34 M | $300.7 M | -68.59% | 16447 |
| 12/30/2020 | ₣873.37 M | $986.47 M | 41215.19% | 8033 |
| 12/30/2019 | ₣2.11 M | $2.18 M | -80.54% | 32288 |
| 12/28/2018 | ₣10.86 M | $11.06 M | -46.34% | 27545 |
| 12/29/2017 | ₣20.24 M | $20.75 M | -65.34% | 25385 |
| 12/30/2016 | ₣58.4 M | $57.24 M | 18683 |
Company Profile
About Relief Therapeutics Holding SA
Relief Therapeutics Holding SA is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative, patent-protected treatments for rare metabolic, dermatological, and pulmonary diseases. Headquartered in Geneva, Switzerland, the company operates across Europe, North America, and internationally.
Key Products & Offerings
- SETOFILM/ONDISSOLVE – For radiotherapy-induced, chemotherapy-induced, and postoperative nausea and vomiting.
- OLPRUVA – A sodium phenylbutyrate treatment for urea cycle disorders and maple syrup urine disease.
- PKU GOLIKE – Designed for the dietary management of phenylketonuria (PKU).
Pipeline Developments
- TYR GOLIKE – Completed Phase III trials for Tyrosinemia treatment.
- RLF-100 (VIP) – In Phase II trials for COVID-19-related ARDS; also in preclinical studies for pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
- HCU GOLIKE – Phase I trials underway for Homocystinuria.
- RLF-TD011 – A hypochlorous acid spray in Phase I trials for wound healing in epidermolysis bullosa.
- RLF-OD32 – Phase I trials targeting phenylketonuria (PKU).
Founded in 2013, Relief Therapeutics continues to advance its mission of delivering transformative therapies for underserved patient populations.
Frequently Asked Questions
-
What is Relief Therapeutics Holding SA's (SWX-RLF) current market cap?As of 07/28/2025, Relief Therapeutics Holding SA (including the parent company, if applicable) has an estimated market capitalization of $36.59 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Relief Therapeutics Holding SA (SWX-RLF) rank globally by market cap?Relief Therapeutics Holding SA global market capitalization ranking is approximately 32367 as of 07/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.